An update from Oncolytics Biotech ( (TSE:ONC) ) is now available.
Oncolytics Biotech Inc. announced it will host a conference call and webcast on March 7, 2025, to discuss its fourth quarter and full-year 2024 financial results and recent operational highlights. This announcement underscores the company’s ongoing efforts to communicate its progress and financial health to stakeholders, reflecting its strategic focus on advancing pelareorep in the oncology sector.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is engaged in advancing treatments for various cancers, including metastatic breast cancer and pancreatic cancer, utilizing pelareorep’s ability to induce anti-cancer immune responses and enhance tumor inflammation. Oncolytics is conducting combination clinical trials and aims for registrational studies, with Fast Track designation from the FDA for its key cancer targets.
YTD Price Performance: -23.25%
Average Trading Volume: 1,238,314
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $55.12M
For a thorough assessment of ONC stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com